63 results about "Immunodeficiency disease" patented technology

Methods of treating, preventing and/or managing an immunodeficiency disease or disorder are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active agent. Methods of boosting humoral immunity are also disclosed.

A novel HIV type O immunodeficiency virus is disclosed which has the designation MVP-2901/94 and which has been deposited with the European collection of animal Cell Cultures (ECACC) under No. V 950121601. The characteristic antigens which can be obtained from the virus and which can be employed for detecting antibodies against retroviruses which are associated with immunodeficiency diseases are also disclosed, as are the partial DNA and amino acid sequences of the virus.

An agaricus bisporus polysaccharide with immunocompetence is a heteropolysaccharide consists of ribose, rhamnose, arabinose, xylose, mannose, glucose, and galactose at a molar ratio of 2.08:4.61:2.45:22.25:36.45:89.22:1.55. The agaricus bisporus polysaccharide is prepared by extracting agaricus bisporus in a water bath; precipitating the extract with ethanol; deproteinizing the precipitate to obtain coarse polysaccharide; processing the coarse polysaccharide by ion exchange column chromatography with an anion exchange packing; eluting with distilled water; carrying out freeze drying; carrying out gel chromatography; eluting with distilled water; carrying out freeze drying to obtain the final product. The agaricus bisporus polysaccharide has immunological enhancement effect, and can serve as adjuvant drug for treating immunodeficiency diseases, such as cancer, or serve as functional health products and foods for enhancing immunity.

This invention relates to novel peptide immunogens that generate an immune response in mammals against HIV gp41, to pharmaceutical compositions that comprise such immunogens, and to methods of treating Immunodeficiency disease, especially HIV infection and AIDS, that employ such pharmaceutical compositions.

The invention discloses application of ginsenoside Rh2 and particularly verifies that ginsenoside can be applied to preparation of inhibitors for inhibiting Treg cells or preparation of compositions for preventing and/or treating tumors with Treg cells increased. The ginsenoside Rh2 is capable of improving balance of T cells in human bodies by inhibition of the Treg cells, autoimmunity can be further enhanced, and accordingly an anti-tumor effect or an immunodeficiency disease improvement effect can be achieved.

The invention provides methods for the administration of an anti-CD 1 antibody for the treatment or prevention of a variety of disorders, such as autoimmune disease, viral infection, bacterial infection, parasitic infection, infection by a eukaryotic pathogen, allergy, asthma, inflammatory condition, graft versus host disease, graft rejection, immunodeficiency disease, spontaneous abortion, pregnancy, and cancer.

Disclosed is a CpG-N ODN gene sequence with high immunological activity CpG-S ODN and antagonism CpG-N ODN and use in preparing medicament for treating infectious diseases, anaphylactic diseases, immunodeficiency diseases, tumor, SIRS and pyaemia.

The invention discloses applications of magnolol, or isomers of magnolol or salts of compounds that are acceptable in pharmaceutical areas to preparation of medicines for treating cachexia and cancers. The cachexia may be caused by selection of the following groups of diseases, states or damage: cancers, immunodeficiency diseases, infectious diseases, autoimmune diseases, metabolic diseases, chronic bowel, liver, kidney, lung and heart diseases, anorexia nervosa, trauma, burning, malabsorption and anemia. In one embodiment, the medicines can be taken by patients that may suffer from cachexia such as cancers. The invention also provides applications of magnolol, or isomers of magnolol or salts of compounds that are acceptable in pharmaceutical areas to preparation of medicines for treating bladder cancers, especially applications to prevention of tumor growth and cancel cell metastasis of bladder cancers and to improvements of animal survival rates.

A method for expressing the thymopeptide alpha 1 by yeast includes such steps as using PCR technique to amplify the whole-length gene of thymopeptide alpha 1, enzyme severing at both ends, and cloning it to yeast while stably expressing it in yeast. The expressed thymopeptide alpha 1 with very high bioactivity can be used to treat tumor, viral and immunodeficiency diseases, and hypothymism, or used as vaccine intensifier.

The invention discloses a Citrin immunodeficiency disease virulence gene SLC25A13 high frequency mutation screening reagent box, and belongs to the biotechnology field. Four kinds of mutations include a I type mutation, a III type mutation, an X type mutation and an XIX type mutation. Sequence of the Citrin immunodeficiency disease virulence gene SLC25A13 high frequency mutation screening primers are displayed as SEQ ID NO.1-8. The Citrin immunodeficiency disease virulence gene SLC25A13 high frequency mutation screening reagent box comprises the primers, dNTPs, deoxyribonucleic acid (DNA) polymerase, DNA polymerase buffer solution and Tas I restriction enzyme components. The reagent box further comprises reagent for extracting genomic DNA from a full blood sample, four kinds of mutation type normality, homozygote and heterozygote comparison DNA, agarose for nucleic acid electrophoresis, DNA Marker and nucleic acid dyestuff. The primers and the reagent box can easily, fast and accurately screen the four high frequency mutations in the SLC25A13.

The invention discloses Citrin immunodeficiency disease pathogenic gene SLC25A13 high-frequency I-type mutation screening primers and kit, belongs to the technical field of biology. Four newly designed primers are provided; a multi-PCR system depending on an ordinary rTaq enzyme is built; whether a sample is I mutation positive or negative or heterozygote can be identified through once PCR and analysis of an electrophoretogram; the primers and the kit are accurate, simple, fast and low in cost. By the screening primers and kit disclosed by the invention, DNA sequencing is not needed; the screening primers and kit are simple, fast and low in cost; the detection result is direct and reliable; the detection time and cost are superior to those of an existing method; the screening primers and kit can be finished by simple common equipment and are suitable for medical and test mechanisms of various regions for fast detection and large-scale population screening of the SLC25A13 high-frequency I-type mutation.

The invention discloses a human immunity enhancer for cancer prevention and treatment. The human immunity enhancer comprises components in parts by weight as follows: 111-222 parts of Echinacea phenol, 144-288 parts of astragaloside, 111-177 parts of chrysin, 333-666 parts of coriolus versicolor polysaccharide, 22-33 parts of diindolymethane, 60-111 parts of resveratrol, 80-111 parts of curcumin,111-222 parts of dihydroquercetin, 111-222 parts of tea polyphenols, 2.22-11.1 parts of L-selenomethionine, 80-130 parts of phosphatidylcholine, 90-140 parts of phosphatidylserine, 444-888 parts of methionine and 3000-4000 parts of a lipidosome matrix emulsion. The natural traditional Chinese medicine extracts and multiple active compounds are matched in proportion, a lipidosome matrix convenientto absorb is adopted, the immunity of the human body can be improved, and cancer, AIDS and other immunodeficiency diseases can be resisted effectively.

The invention relates to application of atractylodes macrocephalaon polysaccharide in medicaments or healthcare products for improving kuffer cell immune function, belonging to the technical field of traditional Chinese medicine. According to the application, homemade PAM (atractylodes macrocephalaon polysaccharide) is adopted for testing the influences on the mouse Kupffer cell immune function. The PAM in vitro is acted to a normal Kupffer cell so as to evaluate the immune function and the cell damage situation according to the phagocytosis quantity of neutral red A540, the secreting quantity of NO and TNF (tumor necrosis factor)-alpha as well as the LDH (lactate dehydrogenase) leakage quantity; after in-vivo mice are injected with the PAM, the indexes of the Kupffer cell, the activity of intracellular ACP (acid phosphatase) as well as the serum ALT and GST are detected. The result shows that the PAM intensifies the phagocytosis to the neutral red caused by Kupffer cell, improves the ACP activity as well as increases the generation amount of NO and TNF-alpha. The PAM in vitro does not increase parenchymal hepatic cell LDH leakage, and has no influence on the activities of sALT and sGST, so that the PAM can activate the Kupffer cell immune function, improves the organism disease resistance, and has an actual application value at the treatment aspect of diseases of immunodeficiency disease, tumor and the like.

The invention provides a method for preparing antibodies from human peripheral blood memory B lymphocytes. The method has the advantages of being convenient, rapid and low in cost. By means of the method, a large number of the antibodies can be prepared in vitro, and the prepared antibodies are very important in preventing infection and treating immunodeficiency diseases.

This invention relates to a novel peptide inhibitor of a HIV fusion that disrupts the internal trimeric coiled-coil of gp41, to a pharmaceutical composition that comprise this inhibitor, and to methods of treating immunodeficiency disease, especially HIV, that employ such a pharmaceutical composition.

The present invention relates to use of an antagonist of BIR1 (B cell immunoglobulin receptor 1) related to the present invention, a method for screening the antagonist, in addition to subtype polypeptides of BIR1, the polynucleotide encoding them and antibodies for the polypeptides.

BIR1 functions as an immunosuppressive receptor, and the antagonist of BIR1 has immunopotentive activity, which is able to use for preventing and/or treating a cancer, an immunodeficiency disease or an infectious disease.